BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Sep 27, 2019
Product Development

Lessons from Healey ALS on how to build platform trials quickly

The first ever platform trial in ALS provides a recipe for getting these collaborative studies off the ground quickly and with early buy-in from companies. Platform trials take advantage of a master protocol to test...
BC Extra | Sep 23, 2019
Clinical News

First adaptive platform trial in ALS could speed development, find new biomarkers

An adaptive platform trial for ALS launched by Mass General could find new biomarkers to serve as surrogate endpoints or predictors of response in the pivotal trial and future studies. Researchers at Massachusetts General Hospital’s...
BC Innovations | Jun 13, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Toll-like receptor 2 (TLR2); CD14 Patient sample and mouse studies identified CD14-targeting peptides that could help treat bacterial...
BC Week In Review | Mar 2, 2009
Company News

Implicit Biosciences, Eli Lilly deal

Implicit acquired exclusive, worldwide rights to Eli Lilly's IC14 for an undisclosed sum, including cash and stock. Implicit expects to begin Phase II testing of the antibody against CD14 to treat acute lung injury in...
BioCentury | Oct 23, 2006

Icos chronicles

Icos chronicles Icos chroniclesIcos (ICOS) has successfully developed one product, Cialis tadalafil, which was discovered with former partner Glaxo Wellcome and repartnered with Eli Lilly (LLY) in October 1998, when it was in Phase II....
BioCentury | Jul 3, 2000
Tools & Techniques

Lilly's sepsis success

The gold standard for sepsis treatments is 28-day all-cause mortality in a Phase III study, an end point that has dashed the dreams of companies and investors for the better part of a decade. Eli...
BioCentury | Nov 8, 1999

ICOS's clinical progress

ICOS's clinical progress Product Indication Status LeukArrest anti-CD11/CD 18 MAb Stroke Phase III (ongoing) Hemorrhagic shock Phase II (future development possible) Myocardial infarction Phase II (discontinued) Multiple sclerosis Phase II (discontinued) Pafase rPAF acetylhydrolase Severe...
BC Week In Review | Oct 4, 1999
Clinical News

IC14: Phase I

In a Phase I challenge study, IC14 prevented a clinical response to a safe dose of endotoxin in 16 healthy volunteers. The antibody blocked the release of pro-inflammatory cytokines and reduced the development of flu-like...
Items per page:
1 - 9 of 9